Dosimetric impact of contrast-enhanced 4d computed tomography for stereotactic body radiation therapy of hepatocelluar carcinoma
Abstract
BACKGROUND: A purpose of the study was to investigate the dosimetric impact of contrast media on dose calculation using average 4D contrast-enhanced computed tomography (4D-CECT) and delayed 4D-CT (d4D-CT) images caused by CT simulation contrast agents for stereotactic body radiation therapy (SBRT) of liver cases.
MATERIALS AND METHODS: Fifteen patients of liver SBRT treated using the volumetric modulated arc therapy (VMAT) technique were selected retrospectively. 4D-CECT, and d4D-CT were acquired with the Anzai gating system and GE CT. For all patients, gross target volume (GTV) was contoured on the ten phases after rigid registration of both the contrast and delayed scans and merged to generate internal target volume (ITV) on average CT images. Region of interest (ROI) was drawn on contrast images and then copied to the delayed images after rigid registration of two average CT datasets. The treatment plans were generated for contrast enhanced average CT, delayed average CT and contrast enhanced average CT with electron density of the heart overridden.
RESULTS: No significant dosimetric difference was observed in plans parameters (mean HU value of the liver, total monitor units, total control points, degree of modulation and average segment area) except mean HU value of the aorta amongst the three arms. All the OARs were evaluated and resulted in statistically insignificant variation (p > 0.05) using one way ANOVA analysis.
CONCLUSIONS: Contrast enhanced 4D-CT is advantageous in accurate delineation of tumors and assessing accurate ITV. The treatment plans generated on average 4D-CECT and average d4D-CT have a clinically insignificant effect on dosimetric parameters.
Keywords: 4D-CECTd4D-CTSBRTHCCHUVMAT
References
- Méndez Ro, Brunner TB, Kirichenko AV. Alternate Fractionation for Hepatic Tumors. Springer, Cham 2017: 173–201.
- Ramm U, Damrau M, Mose S, et al. Influence of CT contrast agents on dose calculations in a 3D treatment planning system. Phys Med Biol. 2001; 46(10): 2631–2635.
- Lee FKH, Chan CCL, Law CK. Influence of CT contrast agent on dose calculation of intensity modulated radiation therapy plan for nasopharyngeal carcinoma. J Med Imaging Radiat Oncol. 2009; 53(1): 114–118.
- Lees J, Holloway L, Fuller M, et al. Effect of intravenous contrast on treatment planning system dose calculations in the lung. Australas Phys Eng Sci Med. 2005; 28(3): 190–195.
- Liauw SL, Amdur RJ, Mendenhall WM, et al. The effect of intravenous contrast on intensity-modulated radiation therapy dose calculations for head and neck cancer. Am J Clin Oncol. 2005; 28(5): 456–459.
- Heydarheydari S, Farshchian N, Haghparast A. Influence of the contrast agents on treatment planning dose calculations of prostate and rectal cancers. Rep Pract Oncol Radiother. 2016; 21(5): 441–446.
- Weber D, Rouzaud M, Miralbell R. Bladder opacification does not significantly influence dose distribution in conformal radiotherapy of prostate cancer. Radiother Oncol. 2001; 59(1): 95–97.
- Izmirli M, Çakır T, Avcu S, et al. Impact of contrast agents on dose algorıthms of planning systems. Int J Radiat Res. 2016; 14(1): 25–30.
- Zabel-du Bois A, Ackermann B, Hauswald H, et al. Influence of intravenous contrast agent on dose calculation in 3-D treatment planning for radiosurgery of cerebral arteriovenous malformations. Strahlenther Onkol. 2009; 185(5): 318–324.
- Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013; 12: 530–547.
- Gupta A, Kumar R, Yadav HP, et al. Feasibility of 4D CT simulation with synchronized intravenous contrast injection in hepatocellular carcinoma. Rep Pract Oncol Radiother. 2020; 25(2): 293–298.
- Helou J, Karotki A, Milot L, et al. 4DCT Simulation With Synchronized Contrast Injection in Liver SBRT Patients. Technol Cancer Res Treat. 2016; 15(1): 55–59.
- Beddar AS, Briere TM, Balter P, et al. 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol. 2008; 87(3): 445–448.
- Dawson L., Zhu A., Knox J. et al. Radiation Therapy Oncology Group RTOG 1112 Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib in Hepatocellular Carcinoma, 2013.
- Thaper D, Kamal R, Singh G, et al. Dosimetric comparison of dynamic conformal arc integrated with segment shape optimization and variable dose rate versus volumetric modulated arc therapy for liver SBRT. Rep Pract Oncol Radiother. 2020; 25(4): 667–677.
- Thaper D, Singh G, Kamal R, et al. Impact of dose heterogeneity in target on TCP and NTCP for various radiobiological models in liver SBRT: different isodose prescription strategy. Biomed Phys Eng Express. 2021; 7(1): 015020.
- Thaper D, Oinam AS, Kamal R, et al. Interplay effect modeling in stereotactic body radiotherapy treatment of liver cancer using volumetric modulated arc therapy. Phys Eng Sci Med. 2021; 44(1): 123–134.
- Xiao J, Li Y, Jiang Q, et al. Hepatic arterial phase and portal venous phase computed tomography for dose calculation of stereotactic body radiation therapy plans in liver cancer: a dosimetric comparison study. Radiat Oncol. 2013; 8: 264.
- Sahbaee P, Abadi E, Segars WP, et al. The Effect of Contrast Material on Radiation Dose at CT: Part II. A Systematic Evaluation across 58 Patient Models. Radiology. 2017; 283(3): 749–757.
- Shibamoto Y, Naruse A, Fukuma H, et al. Influence of contrast materials on dose calculation in radiotherapy planning using computed tomography for tumors at various anatomical regions: a prospective study. Radiother Oncol. 2007; 84(1): 52–55.